ES2089844T3 - Sistema de administracion de medicamentos a base de dicetopiperazina. - Google Patents

Sistema de administracion de medicamentos a base de dicetopiperazina.

Info

Publication number
ES2089844T3
ES2089844T3 ES93920574T ES93920574T ES2089844T3 ES 2089844 T3 ES2089844 T3 ES 2089844T3 ES 93920574 T ES93920574 T ES 93920574T ES 93920574 T ES93920574 T ES 93920574T ES 2089844 T3 ES2089844 T3 ES 2089844T3
Authority
ES
Spain
Prior art keywords
microparticles
stable
diketopiperazine
drug
dicetopiperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920574T
Other languages
English (en)
Inventor
Robert Feldstein
John Glass
Solomon S Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Pharmaceutical Discovery Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Discovery Corp filed Critical Pharmaceutical Discovery Corp
Application granted granted Critical
Publication of ES2089844T3 publication Critical patent/ES2089844T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats

Abstract

SE HAN DESARROLLADO SISTEMAS DE DISTRIBUCION DEL MEDICAMENTO BASANDOSE EN LA FORMACION DE MICROPARTICULAS DE DICETOPIPERAZINA (O ANALOGOS). EN LA PUESTA EN PRACTICA PREFERENTE LA MICROPARTICULA ES ESTABLE A PH BAJO Y SE DESINTEGRA A PH FISIOLOGICO, Y ES PARTICULARMENTE UTIL PARA LA DISTRIBUCION ORAL DE MEDICAMENTOS. EN LA PUESTA EN PRACTICA MAS PREFERENTE LAS MICROPARTICULAS SE FORMAN EN PRESENCIA DEL MEDICAMENTO QUE VA A SER DISTRIBUIDO, POR EJEMPLO INSULINA O HEPARINA. LOS INTERMEDIOS SINTETICOS DE LA DICETOPIPERAZINA SE FORMAN PREFERIBLEMENTE MEDIANTE CICLODIMERIZACION PARA FORMAR DERIVADOS DE LA DICETOPIPERAZINA EN CONDICIONES ELEVADAS BAJO CONDICIONES DE DESHIDRATACION, LUEGO SE PRECIPITAN CON EL MEDICAMENTO PARA INCORPORARSE EN MICROPARTICULAS.
ES93920574T 1992-03-11 1993-03-11 Sistema de administracion de medicamentos a base de dicetopiperazina. Expired - Lifetime ES2089844T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/849,186 US5352461A (en) 1992-03-11 1992-03-11 Self assembling diketopiperazine drug delivery system

Publications (1)

Publication Number Publication Date
ES2089844T3 true ES2089844T3 (es) 1996-10-01

Family

ID=25305266

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920574T Expired - Lifetime ES2089844T3 (es) 1992-03-11 1993-03-11 Sistema de administracion de medicamentos a base de dicetopiperazina.

Country Status (11)

Country Link
US (2) US5352461A (es)
EP (1) EP0630236B1 (es)
JP (1) JP2617273B2 (es)
AT (1) ATE132744T1 (es)
AU (1) AU680408B2 (es)
CA (1) CA2131366C (es)
DE (1) DE69301311T2 (es)
DK (1) DK0630236T3 (es)
ES (1) ES2089844T3 (es)
GR (1) GR3019622T3 (es)
WO (1) WO1993018754A1 (es)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US5811127A (en) 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5401516A (en) 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
AU6819294A (en) 1993-04-22 1994-11-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US20010003001A1 (en) 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5958457A (en) 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5466259A (en) * 1994-03-07 1995-11-14 Durette; Jean-Francois Orbital implant and method
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
NZ298169A (en) 1994-12-22 1999-09-29 Astra Ab Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
CN1151836C (zh) 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5824345A (en) * 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US5667806A (en) 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
WO1997010197A1 (en) 1995-09-11 1997-03-20 Emisphere Technologies, Inc. METHOD FOR PREPARING φ-AMINOALKANOIC ACID DERIVATIVES FROM CYCLOALKANONES
JP2000500461A (ja) * 1995-11-13 2000-01-18 スミスクライン・ビーチャム・コーポレイション 血液調節化合物
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
EP0904065A4 (en) 1996-06-14 2000-06-14 Emisphere Tech Inc MICRO-ENCLOSED FRAGRANCES AND PRODUCTION METHOD
CA2243643A1 (en) 1996-11-18 1998-05-28 Susan Haas Methods and compositions for inducing oral tolerance in mammals
US5876710A (en) 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US5891237A (en) * 1997-10-08 1999-04-06 Millennium Inorganic Chemicals, Ltd. Production of free flowing spheres using partially neutralized fatty acid
ES2242412T3 (es) 1998-07-27 2005-11-01 Emisphere Technologies, Inc. Compuestos que permiten administrar agentes activos y composiciones a base de estos compuestos.
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
WO2000007979A2 (en) * 1998-08-07 2000-02-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2000040203A2 (en) 1999-01-08 2000-07-13 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
WO2000050050A1 (en) * 1999-02-23 2000-08-31 Isis Pharmaceuticals, Inc. Multiparticulate formulation
AU3378100A (en) 1999-02-26 2000-09-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
EP1196430B1 (en) * 1999-06-29 2012-02-15 MannKind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
AU2012201760B2 (en) * 1999-06-29 2015-04-16 Mannkind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
CA2391660C (en) 1999-11-15 2009-11-24 Biocure, Inc. Responsive polymeric hollow particles
WO2001044199A1 (en) 1999-12-16 2001-06-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7833549B2 (en) * 2000-01-19 2010-11-16 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US6808707B2 (en) * 2000-02-04 2004-10-26 Matrix Design Wound healing compositions and methods using tropoelastin and lysyl oxidase
DE10019879A1 (de) * 2000-04-20 2001-10-25 Degussa Verfahren zur Herstellung von 2,5-Diketopiperazinen, neue 2,5-Diketopiperazine und deren Verwendung
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
WO2002062797A2 (en) * 2000-12-29 2002-08-15 Celltech R & D, Inc. Pharmaceutical uses and synthesis of diketopiperazines
US20030225300A1 (en) * 2001-04-19 2003-12-04 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
AU2003205226A1 (en) * 2002-01-18 2003-09-02 Mannkind Corporation Compositions for treatment or prevention of bioterrorism
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
US7053034B2 (en) * 2002-04-10 2006-05-30 Salvona, Llc Targeted controlled delivery compositions activated by changes in pH or salt concentration
US20050238724A1 (en) * 2002-04-23 2005-10-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
AU2003231777C1 (en) * 2002-04-29 2009-10-29 Supernus Pharmaceuticals, Inc. Pharmaceutical formulations with improved bioavailability
US20040038865A1 (en) * 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
CA2493478C (en) * 2002-08-01 2014-11-18 Mannkind Corporation Cell transport compositions and uses thereof
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040171518A1 (en) * 2003-02-27 2004-09-02 Medtronic Minimed, Inc. Compounds for protein stabilization and methods for their use
US20040224024A1 (en) * 2003-04-23 2004-11-11 Massachusetts Institute Of Technology Controlled drug release formulations containing polyion complexes
JP2007500747A (ja) 2003-05-15 2007-01-18 ディーエムアイ バイオサイエンシズ インコーポレイテッド T細胞媒介性疾患の処置
CA2533128A1 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Bioactive compositions comprising triazines
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
WO2005080983A2 (en) * 2003-09-23 2005-09-01 Wisconsin Alumni Research Foundation Using liquid crystals to detect affinity microcontact printed biomolecules
US7795007B2 (en) 2003-09-23 2010-09-14 Wisconsin Alumni Research Foundation Detection of post-translationally modified peptides with liquid crystals
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
NZ548980A (en) * 2004-01-12 2009-10-30 Mannkind Corp Reducing serum proinsulin levels in type 2 diabetics
US20070027063A1 (en) * 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
JP2005209106A (ja) * 2004-01-26 2005-08-04 Nec Corp 携帯通信端末、受信メール管理方法、プログラムおよび記録媒体
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
PL1740154T3 (pl) * 2004-03-12 2009-11-30 Biodel Inc Kompozycje insuliny o ulepszonym wchłanianiu
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
PL1791542T3 (pl) * 2004-08-23 2015-11-30 Mannkind Corp Sole diketopiperazyny do dostarczania leków
JP2008510825A (ja) * 2004-08-23 2008-04-10 マンカインド コーポレイション ホスホジエステラーゼ5型の阻害剤の肺送達
EP1858486A2 (en) * 2005-01-10 2007-11-28 MannKind Corporation Methods and compositions for minimizing accrual of inhalable insulin in the lungs
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
AU2006290870B2 (en) 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
ATE443658T1 (de) * 2005-11-21 2009-10-15 Mannkind Corp Pulverabgabe und -erfassungsvorrichtung und - verfahren
EP2497484A3 (en) 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
MX2008013165A (es) 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
KR101438839B1 (ko) * 2006-04-14 2014-10-02 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 (glp-1) 약제학적 제제
BRPI0714616A2 (pt) * 2006-08-04 2013-06-11 Manus Pharmaceuticals Canada Ltd composto bioativo multifuncional, composiÇço farmacÊutica, e, uso de um composto
DE602007008125D1 (de) 2006-10-31 2010-09-09 Surmodics Pharmaceuticals Inc Kugelförmige polymer-teilchen
MX2010004508A (es) * 2007-10-24 2010-07-02 Mannkind Corp Suministro de agentes activos.
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
CA2703338A1 (en) 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
AU2009204309B2 (en) * 2008-01-04 2012-11-22 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
JP5856843B2 (ja) * 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ,インコーポレイテッド ジケトピペラジンを用いた医薬組成物
DK2570147T3 (da) 2008-06-13 2018-01-29 Mannkind Corp Tørpulverinhalator og system til lægemiddelindgivelse
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
ES2443300T3 (es) 2008-08-05 2014-02-18 Mannkind Corporation Módulos dispensadores de polvo y conjuntos dispensadores de polvo
TWI532497B (zh) * 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
MX2011004859A (es) 2008-11-07 2011-08-03 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
ES2531009T3 (es) * 2008-12-29 2015-03-09 Mannkind Corp Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
DK2379100T3 (en) 2009-01-08 2014-12-01 Mannkind Corp Treatment of hyperglycemia with GLP-1
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
TWI528982B (zh) 2009-03-04 2016-04-11 曼凱公司 改良的乾粉藥物輸送系統
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
ES2751107T3 (es) * 2009-06-12 2020-03-30 Mannkind Corp Micropartículas de dicetopiperazina con contenido de isómeros definido
US8734845B2 (en) * 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011017554A2 (en) 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
CN104801215B (zh) * 2009-11-02 2017-11-17 曼康公司 以沉淀过程产生药物颗粒的反应器
CA2779613C (en) 2009-11-02 2017-10-10 Mannkind Corporation Apparatus and method for cryogranulating a pharmaceutical composition
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
US9140651B2 (en) 2010-05-07 2015-09-22 Mannkind Corporation Determining percent solids in suspension using raman spectroscopy
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
CN107854454A (zh) 2010-11-09 2018-03-30 曼金德公司 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物
SG10201802008TA (en) * 2011-02-10 2018-04-27 Mannkind Corp Formation of n-protected bis-3,6-(4-aminoalkyl) -2,5,diketopiperazine
EP2691443B1 (en) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Conjugated lipomers and uses thereof
MY180552A (en) 2011-04-01 2020-12-02 Mannkind Corp Blister package for pharmaceutical cartridges
AU2012242768B2 (en) 2011-04-12 2017-10-12 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP2717861A1 (en) * 2011-06-06 2014-04-16 Perosphere, Inc. Bioadhesive drug delivery compositions
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
SG10201608087WA (en) * 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
EP4074694A1 (en) 2011-10-27 2022-10-19 Massachusetts Institute Of Technology Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof
MX355446B (es) 2011-10-28 2018-04-18 Ampio Pharmaceuticals Inc Tratamiento de rinitis.
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
US9011832B2 (en) 2012-02-09 2015-04-21 Novus International, Inc. Heteroatom containing cyclic dimers
WO2013142969A1 (en) * 2012-03-28 2013-10-03 Jian Ping Gao Urethanes and ureas and processes
WO2013162764A1 (en) 2012-04-27 2013-10-31 Mannkind Corp Methods for the synthesis of ethylfumarates and their use as intermediates
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
MX2015000395A (es) 2012-07-12 2015-04-10 Novus Int Inc Composiciones de matriz y capa para proteccion de bioactivos.
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
PL2968586T3 (pl) 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
EP4276176A3 (en) 2013-10-22 2024-01-10 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
EP3060258A1 (en) 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
NZ718817A (en) 2013-10-22 2020-07-31 Massachusetts Inst Technology Lipid formulations for delivery of messenger rna
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10336788B2 (en) 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
EA201691696A1 (ru) 2014-04-25 2017-03-31 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
AU2015266764B2 (en) 2014-05-30 2019-11-07 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
CN106795142B (zh) 2014-06-24 2022-11-04 川斯勒佰尔公司 用于递送核酸的立体化学富集组合物
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
KR20170045274A (ko) 2014-08-18 2017-04-26 앰피오 파마슈티컬스 인코퍼레이티드 관절 징후의 치료
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
US10500249B2 (en) 2014-11-17 2019-12-10 Moerae Matrix Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
BR112017019343A2 (pt) 2015-03-12 2018-05-02 Moerae Matrix Inc uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
SI3310764T1 (sl) 2015-06-19 2023-06-30 Massachusetts Institute Of Technology Z alkenilom substituirani 2,5-piperazindioni in njihova uporaba v sestavkih za dostavo sredstva subjektu ali celici
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN114904100A (zh) * 2016-01-29 2022-08-16 曼金德公司 干粉吸入器
TW201809049A (zh) 2016-03-31 2018-03-16 盧伯利索先進材料有限公司 生物可分解及/或生物可吸收的熱塑性聚胺甲酸酯
MA47603A (fr) 2017-02-27 2020-01-01 Translate Bio Inc Nouvel arnm cftr à codons optimisés
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
WO2019071258A1 (en) * 2017-10-06 2019-04-11 The Regents Of The University Of California SELF-ASSEMBLED MICROCAPSULES FOR ENCAPSULATION AND OPTICALLY CONTROLLED CARGO DELIVERY
WO2019237028A1 (en) * 2018-06-07 2019-12-12 Mannkind Corporation Composition and method for inhalation
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1155036A (en) * 1966-07-08 1969-06-11 Ethan Allan Brown Injectionable Substance
GB1255805A (en) * 1967-12-16 1971-12-01 Albert Ag Chem Werke Improvements in delayed release pharmaceutical preparations and stabilisation of vitamins
GB1377074A (en) * 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
US4400330A (en) * 1982-07-29 1983-08-23 Stauffer Chemical Company Method for preparation of N-phosphonomethylglycine
US4694082A (en) * 1985-09-23 1987-09-15 Monsanto Company Compound 1,4-diisopropyl-2,5-diketopiperazine
NL8720442A (nl) * 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5057317A (en) * 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
US4976968A (en) * 1989-02-24 1990-12-11 Clinical Technologies Associates, Inc. Anhydrous delivery systems for pharmacological agents
US4983402A (en) * 1989-02-24 1991-01-08 Clinical Technologies Associates, Inc. Orally administerable ANF
WO1991006287A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system

Also Published As

Publication number Publication date
EP0630236A1 (en) 1994-12-28
CA2131366A1 (en) 1993-09-30
US5352461A (en) 1994-10-04
WO1993018754A1 (en) 1993-09-30
JPH07506818A (ja) 1995-07-27
AU680408B2 (en) 1997-07-31
GR3019622T3 (en) 1996-07-31
ATE132744T1 (de) 1996-01-15
US5503852A (en) 1996-04-02
DK0630236T3 (da) 1996-06-03
AU3804493A (en) 1993-10-21
DE69301311D1 (de) 1996-02-22
CA2131366C (en) 2003-09-23
JP2617273B2 (ja) 1997-06-04
DE69301311T2 (de) 1996-08-22
EP0630236B1 (en) 1996-01-10

Similar Documents

Publication Publication Date Title
ES2089844T3 (es) Sistema de administracion de medicamentos a base de dicetopiperazina.
DE69637441D1 (de) Verabreichung unlöslicher arzneistoffe
ATE81287T1 (de) Am zielorgan wirkendes enterales abgabesystem.
MX9100249A (es) Sistema para suministrar medicamentos y proceso para preparar el mismo
ATE122879T1 (de) Verabreichungsformen für pharmaka.
GR3031448T3 (en) Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
ATE84705T1 (de) Ein freifliessendes granulat, enthaltend ibuprofen und ein herstellunsgverfahren.
GB2217201A (en) Delivery systems for pharmacological agents
DE69428040T2 (de) Orale darreichungsform
DE69226369D1 (de) System mit erhöhender Hautpenetration für verbesserte topische Verabreichung von Arzneimitteln
MY132812A (en) Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
DE68903852T2 (de) Hochmolekulare prodrogenderivate von entzuendungshemmenden arzneimitteln.
ID28160A (id) Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.
Robinson et al. Comparison of histamine release induced by morphine and oxymorphone administration in dogs
DE3765243D1 (de) Ibuprofen und codein enthaltende, stabile, feste arzneimittel.
DE3860967D1 (de) Arzneimittel in form stabiler suspendiermittel freier sucralfat-suspensionen.
IT1306644B1 (it) Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
MD586C2 (ro) Substanţă medicamentoasă cu acţiune antihipotensivă "Difetur"
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
ES2146200T3 (es) Medicamentos inducidos peritonealmente.
BR0313613A (pt) Variantes do principal alérgeno phl p 1 de capim-timóteo
ATE56706T1 (de) 4-methoxyisophthalsaeurederivat mit pharmakologischer wirksamkeit gegen thromboembolische erkrankung und verfahren zu dessen herstellung.
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 630236

Country of ref document: ES

FG2A Definitive protection

Ref document number: 630236

Country of ref document: ES